Experiment 1027225
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | SPREMULLI,E: SCHULZ,JJ: SPECKHART,VJ: WAMPLER,GL:. (1980). PHASE II STUDY OF VM-26 IN ADULT MALIGNANCIES.. 64() |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE II STUDY IN 96 PATIENTS WITH A VARIETY OF MALIGNANCIES. TEN PATIENTS WERE EXCLUDED FROM THE ANALYSIS. RESPONSES WERE SEEN IN JEJUNAL ADENOCARCINOMA(1/1 PATIENT),COLORECTAL CARCINOMA(2/14),LYMPHOMA(1/4)AND SMALL CELL CARCINOMA OF THE LUNG(1/2). PARTIAL RESPONSES WERE RECORDED IN BREAST CARCINOMA(4/11),SQUAMOUS CELL CARCINOMA OF THE LUNG(1/2),MALIGNANT GLIOMA(2/10)AND OVARIAN CARCINOMA(1/2). THE TITLE COMPOUND WAS FOUND TO BE A DRUG WITH LOW ACTIVITY BUT HIGH ACCEPTABILITY IN THIS ADVANCED CANCER POPULATION. MARROW DEPRESSION WAS THE MAIN TOXIC EFFECT AND WAS EASILY MANAGED. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |